Nf. Col et al., PATIENT-SPECIFIC DECISIONS ABOUT HORMONE REPLACEMENT THERAPY IN POSTMENOPAUSAL WOMEN, JAMA, the journal of the American Medical Association, 277(14), 1997, pp. 1140-1147
Objective.-To examine the effect of hormone replacement therapy on lif
e expectancy in postmenopausal women with different risk profiles for
heart disease, breast cancer, and hip fracture. Design.-Decision analy
sis using a Markov model, Published regression models were used to lin
k risk factors to disease incidence and to estimate the lifetime risks
of developing coronary heart disease (CHD), breast cancer, hip fractu
re, and endometrial cancer, The impact of hormone therapy on disease i
ncidence was estimated from published epidemiologic studies. Setting.-
Mathematical model applicable to primary care, Interventions.-Treatmen
t with hormone replacement therapy or no hormone replacement therapy.
Main Outcome Measure.-Life expectancy. Results.-Hormone replacement th
erapy should increase life expectancy for nearly all postmenopausal wo
men, with some gains exceeding 3 years, depending mainly on an individ
ual's risk factors for CHD and breast cancer, For women with at least
1 risk factor for CHD, hormone therapy should extend life expectancy,
even for women having first-degree relatives with breast cancer, Women
without any risk factors for CHD or hip fracture, but who have 2 firs
t-degree relatives with breast cancer, however, should not receive hor
mone therapy. Conclusions.-The benefit of hormone replacement therapy
in reducing the likelihood of developing CHD appears to outweigh the r
isk of breast cancer for nearly all women in whom this treatment might
be considered, Our analysis supports the broader use of hormone repla
cement therapy.